Cargando…
Interleukin 6 Receptor Is an Independent Prognostic Factor and a Potential Therapeutic Target of Ovarian Cancer
Ovarian cancer remains the most lethal gynecologic cancer and new targeted molecular therapies against this miserable disease continue to be challenging. In this study, we analyzed the expressional patterns of Interleukin-6 (IL-6) and its receptor (IL-6R) expression in ovarian cancer tissues, evalua...
Autores principales: | Isobe, Aki, Sawada, Kenjiro, Kinose, Yasuto, Ohyagi-Hara, Chifumi, Nakatsuka, Erika, Makino, Hiroshi, Ogura, Tomonori, Mizuno, Tomoko, Suzuki, Noriko, Morii, Eiichi, Nakamura, Koji, Sawada, Ikuko, Toda, Aska, Hashimoto, Kae, Mabuchi, Seiji, Ohta, Tsuyoshi, Morishige, Ken-ichirou, Kurachi, Hirohisa, Kimura, Tadashi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4319819/ https://www.ncbi.nlm.nih.gov/pubmed/25658637 http://dx.doi.org/10.1371/journal.pone.0118080 |
Ejemplares similares
-
The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma
por: Kinose, Yasuto, et al.
Publicado: (2015) -
Plasminogen activator inhibitor-1 is an independent prognostic factor of ovarian cancer and IMD-4482, a novel plasminogen activator inhibitor-1 inhibitor, inhibits ovarian cancer peritoneal dissemination
por: Nakatsuka, Erika, et al.
Publicado: (2017) -
Integrin Inhibitors as a Therapeutic Agent for Ovarian Cancer
por: Sawada, Kenjiro, et al.
Publicado: (2012) -
Effects of minodronate in postmenopausal women with osteoporosis who received prior treatment with raloxifene
por: Toda, Aska, et al.
Publicado: (2017) -
Downregulation of miR-194-5p induces paclitaxel resistance in ovarian cancer cells by altering MDM2 expression
por: Nakamura, Koji, et al.
Publicado: (2019)